Pharmaceutical Executive
Acting on the belief that states should respect agency rulings involving labeling and advertising, FDA filed legal briefs challenging judges that second-guess its authority.
Acting on the belief that states should respect agency rulings involving labeling and advertising, FDA filed legal briefs challenging judges that second-guess its authority. The agency's top lawyer, Daniel Troy, maintains that FDA is entitled to "deference" by state governments in scientific and regulatory issues, as seen in three important cases now before the courts:
Need for a black-box warning about suicide for Zoloft (sertraline). FDA recently filed an amicus brief in the Ninth Circuit Court of Appeals in a case involving a California woman claiming that her husband committed suicide after taking Zoloft and that Pfizer was negligent in failing to provide adequate warning. FDA says it weighed information about the need for stronger warnings on anti-depressants for that effect and decided that the evidence did not support such a finding. A federal district court ruled that FDA's regulation of drug labels does not preempt all state court actions, but FDA maintains that the judge did not adequately review all the evidence.
TV ad claims for Paxil (paroxetine). In August, FDA challenged a federal court ruling regarding DTC ad claims that GlaxoSmithKline's Paxil (paroxetine) is not "habit forming." The judge had agreed with plaintiffs that GSK ads were misleading and ordered them off the air. FDA counters that it reviewed the issue and determined that GSK's claim is legitimate and different from the adverse events arising from discontinuing the therapy too quickly.
Stop-smoking product use by pregnant women. FDA also is arguing against a court ruling-Dowhal v. SmithKlineBeecham-that California's Proposition 65 requires manufacturers of anti-smoking therapies to warn pregnant women not to use them. That ruling contradicts FDA experts' finding that such a warning might deter pregnant women from making efforts to stop smoking, which would do even more harm to a fetus. A coalition of manufacturer associations is asking the California Supreme Court to review and overturn the lower state court decision.
Troy told attendees at the Food and Drug Law Institute marketing conference last month that those court actions pose a serious challenge to FDA's control over pharma labels and marketing materials. The agency can't have 50 states setting different standards for drug ads, commented the chief counsel. Troy says such issues could end up before the Supreme Court.
In the meantime, he noted that the same thinking applies to first amendment rights cases. If FDA deserves deference from the courts on scientific and regulatory decisions, it similarly should not have to collect new patient comprehension data to defend its decisions on DTC advertising against charges of violating marketers' right to free speech.
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
2 Commerce Drive
Cranbury, NJ 08512